Dr. Diefenbach on Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in FL

Video

In Partnership With:

Catherine M. Diefenbach, MD, discusses polatuzumab vedotin (Polivy) plus obinutuzumab (Gazyva) and lenalidomide (Revlimid) in patients with follicular lymphoma.

Catherine M. Diefenbach, MD, associate professor, Department of Medicine, clinical director of lymphoma, NYU Langone Medical Center, discusses polatuzumab vedotin (Polivy) plus obinutuzumab (Gazyva) and lenalidomide (Revlimid) in patients with follicular lymphoma.

Fifty-six patients were enrolled in the phase Ib/II GO29834 trial, which treated heavily pretreated patients with follicular lymphoma. The patient population had a median of 3 prior lines of therapy; 50% were refractory to last line of prior regimen, and 25% had progression of diease within 2 years of their initial chemotherapy, which is an independent negative prognostic factor. At the end of the trial 39 patients were evaluated for efficacy ofpolatuzumab vedotin plus obinutuzumab and lenalidomide.

All patients had ≥1 adverse event (AE). The most common grade 3/4 AEs were myelosuppression; however, with growth factor support, most patients were able to continue on therapy. Eleven percent incidence of neutropenic fever, which Diefenbach theorizes is due to the patients being heavily pretreated.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD